We found that the expression level of STAT1 in the treatment response group of patients with NSCLC who received PD-1/PD-L1 immunotherapy was significantly higher than that in the non-response group (p = 0.0448) (Supplementary Figure S5C). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.